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David Tuveson, Director of the Cancer Center at Cold Spring Harbor
Laboratory, is a clinician-scientist with a longstanding interest in
understanding and treating pancreatic cancer. Since developing the
first mouse model of pancreatic cancer in 2002, the Tuveson lab has
made a series of discoveries that shed light on the molecular drivers
of this disease and provide promising therapeutic avenues for a
malignancy that is notoriously challenging to treat. In collaboration
with Hans Clevers, David developed the first pancreatic cancer
organoids, which revolutionized the field by providing a powerful
model system for basic discoveries and advancement of
personalized medicine. Here, David talks to Ross Cagan about his
path from chemistry student to world-renowned oncologist,
highlighting how his colleagues, mentors and patient interactions
shaped his research interests and unique approach to scientific
discovery. As well as discussing the story behind some of his
breakthroughs, he provides tips on running a lab and succeeding in or
outside academia.
David Tuveson was born in Chicago, in 1966. He received his BSc
in Chemistry from Massachusetts Institute of Technology (M.I.T.)
in 1987, and after completing his MD PhD at Johns Hopkins School
of Medicine in 1994, he returned to Boston to undertake an Internal
Medicine Residency at Brigham & Women’s Hospital. Settling on
oncology as his specialist area, David pursued a fellowship at the
Dana-Farber Cancer Institute between 1997 and 2000. As part of his
post-doctoral training, David worked with George Demetri to
develop c-Kit inhibitors as a treatment for gastrointestinal stromal
tumors, and also created the first KRAS-dependent lung cancer
mouse models with Tyler Jackson at MIT. He became an Assistant
Professor at the University of Pennsylvania in 2002, and it was here
that he succeeded in developing the first mouse models of ductal
pancreatic cancer. In 2006, he moved to the UK where he founded
and directed the Cambridge Pancreatic Cancer Centre. During his
years in Cambridge, he brought to light a key role for stromal
interactions in impeding drug delivery into pancreatic tumors, and
these findings formed the basis of clinical trials for this particularly
aggressive type of cancer. He returned to the USA in 2012 to direct
the Cancer Therapeutics Initiative at Cold Spring Harbor Laboratory
(CSHL), and to date remains dedicated to straddling the clinic and
lab to improve the outcome for pancreatic cancer patients. His lab
uses mouse models to explore the molecular mechanisms that drive
pancreatic cancer, and in 2012 they partnered with the Clevers’ lab
at the Hubrecht Institute to develop pancreatic cancer organoids –
three-dimensional tissue-based models of the disease. David was
recently appointed as Director of the National Cancer Institute
(NCI)-designated Cancer Center at CSHL, and continues to practice
medical oncology with an adjunct appointment at Memorial-Sloan
Kettering and a clinical affiliation with Northwell Health. He has
been honoured with several awards, including the Rita Allen
Foundation Scholar Award, the Waldenstrom Award and the
Hamdan Award.
Let’s start with your background. Have you always been
interested in science?
My parents played an important role. I would go outside with a net
and catch things that fly or swim and bring them home to try to
identify them – my parents really encouraged this. Growing up, my
curiosity was mostly embedded in nature, and I loved exploring the
myriad of shapes, sizes, colors and patterns that occur naturally. I
was fascinated with the outdoor world, and I suspect today this
experience has been replaced by sitting on a couch for many
youngsters. At school, I was able to channel my curiosity towards
understanding and learning new things. Then, when I got to
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university, I was surrounded by people much smarter than I was and
that was probably the shifting event. I’ve always been a good
observer, but my peers were better at quantifying things and solving
problems. So I decided to get better at the quantitative stuff. I
majored in Chemistry at MIT, not necessarily because I loved it, but
because it was hard. My mentors at MIT were amazing. My
freshman advisor was Robert Langer; a brilliant, clever, creative guy
who I’ve kept in touch with over the years. (Karl) Barry Sharpless
was then my advisor in chemistry, and he is also incredibly creative;
he worked on developing new ways to synthesize compounds and
he won a Nobel Prize in Chemistry for his work. Barry is the person
who helped me to channel my interest in chemistry towards solving
problems in life sciences, and he got me to think about going to
medical school, which is ultimately what I chose to do.
Can you tell us a bit about your experiences and mentors at
Johns Hopkins?
Medical school was one of the most profound experiences of my
life. The coursework in the beginning was a little bit slow, but it
picked up as soon as patients got involved. For my research project, I
wanted to work on the science of sleep, but I struggled to find an
advisor. This was before there were any genes on circadian rhythm
cloned, and people wanted to work on areas that were maybe more
focused, such as olfaction. Instead, I ended up working on the
immune system. This was a part of physiology that was ‘coming of
age’ thanks to advances in molecular biology, and I was lucky
enough to do a rotation in Doug Fearon’s lab. Doug is an
immunologist and he had moved to John Hopkins from Harvard
where he had done his seminal work on the complement system.
Working with Doug gave me my first proper laboratory exposure
and experience of ‘deep science’, and I loved it. He is very smart,
very serious and he was a great role model.
“Cancer patients reminded me of
experiments where you didn’t know if you
were going in the right direction, you
didn’t know what was going to happen,
you just knew you cared.”
What inspired your interest in oncology?
After finishing my MD PhD, I decided to do an Internal Medicine
Residency in Boston. I found practicing as a doctor easier than
doing research because you can see the ‘finish line’ – you can
actually help people in a quick period of time, though not always.
The ‘not always’ patients oftentimes had cancer. Cancer patients
reminded me of experiments where you didn’t know if you were
going in the right direction, you didn’t know what was going to
happen, you just knew you cared. It disturbed me that we had so
little to offer cancer patients, which was a driving force behind my
decision to go into oncology. It was between this or cardiology,
which I still think is a lot more fun because once you learn how to
fix a person’s heart you can put them back in their office or on their
golf course; in cancer we don’t have any of those kind of ‘baby
delivery’ moments. So my decision wasn’t based on science so
much as a desire to help patients.
Why did you focus on pancreatic cancer? What makes this
type of cancer such a ‘rugged opponent’?
Going back a little, when I was a house officer at the Brigham in
1994, I thought I was going to end up being an HIV doctor, because
at the time there was nothing we could offer these patients. But as it
turned out, that was the year that combination antiretroviral therapy
came out, and the patients went from dying in front of our eyes
because of opportunistic infections, to getting better. Pancreatic
cancer was a bigger challenge. At the time, targeted therapy didn’t
exist and the patients that I saw never got better, and nobody was
interested. I ran around Boston trying to find somebody to talk to
about the disease, and was lucky to get steered towards a new faculty
member at MIT - Tyler Jacks. I met Tyler, and he wasn’t that thrilled
with the idea of having a medically trained post-doc in his lab, but I
think the fact that I had research experience persuaded him. So in
1996, I became his first medical post-doc. I worked on trying to
create a model of pancreatic cancer, and I hadn’t succeeded even by
2002 when I got recruited by UPenn. After I arrived at UPenn, I bred
the mice that I made at MIT together, and within the first few
months it was very clear they were showing pancreatic pathology –
the model itself was thus born at UPenn, but gestated at MIT. Tyler
was very generous; he allowed me to take the whole project with me
and was very supportive of my career. This is how I try to be with all
my post-docs. I tell them, ‘come and work on your problem, and I
cannot promise you that you’ll solve it but I can promise you that
I’m going to support you, come hell or high water’. I also tell my lab
that my job as a pancreatic cancer researcher – and theirs – is to put
me out of work. For example, the characterization of the first mouse
models was massively accelerated by a long-time colleague and
friend who joined our lab as an instructor a fewmonths after I started
at Penn, Sunil Hingorani. Sunil was so productive that hewas able to
get his own independent faculty position within three years! Sunil’s
own lab has accelerated the field greatly, and I am always looking
for the next Sunil. I’ve been working on pancreatic cancer for 20
years now, and I would have to say that all I’ve done is to help the
field understand the problem better; no solving has happened,
though we’re getting closer.
“I’ve been working on pancreatic cancer
for 20 years now, and I would have to say
that all I’ve done is to help the field
understand the problembetter; no solving
has happened, though we’re getting
closer.”
How has your time in the lab changed who you are as a
doctor?
I don’t spend a lot of my time seeing patients any more, and spend
more time on the research side. I think that the lab offers the best
hope for patients; for example, by identifying better therapies or
developing a test that can detect pancreatic cancer early. These are
two key challenges that we are working on addressing in our lab.
I feel lucky that I have the opportunity to do both medicine and
research - because I spent so many years learning to become a
physician, and really enjoyed it, I can speak both ‘languages’ and
I have a feel for what we need to do better to help patients. Not
everything we have worked on in the lab has borne fruit in the clinic
yet, but everything we have worked on has helped us to understand
the clinical problem better and brought us a step closer. What I do is
very exciting, but it’s also very sobering. The time I spend with
patients, I’m constantly reminded we have to move faster and move
smarter to come up with things that don’t just equal great papers but
could actually impact patients.
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How has the pancreatic cancer community changed over 20
years?
Well there are now thousands of brilliant researchers working on
pancreatic cancer, which is great. The tools have also changed. We
now have models that we can use to follow cancer progression.
These models are important because patients get sick so fast that you
can’t really study them – it’s not possible, it’s not ethical – you just
focus on alleviating their suffering. When patients are that sick, they
also don’t qualify for clinical trials and so you don’t learn
scientifically what they’re going through. I think the science that
we have developed –my lab and many of the people that have come
into the field – offers a ray of sunlight into this dark room. I’m not a
chemist any more, but there are chemists now working on the
disease as well as geneticists. There are people trying harder than
ever before to cure this disease.
“What I do is very exciting, but it’s also
very sobering. The time I spend with
patients, I’mconstantly reminded we have
to move faster and move smarter to come
up with things that don’t just equal great
papers but could actually impact
patients.”
Talking about trying – a few years ago you ran a trial for a
stromal hedgehog inhibitor, which failed to slow progression
of pancreatic cancer. What was the background behind this
trial and what did you learn from the experience?
The experiments were done by a terrific post-doc, Ken Olive, back
when my lab was in Cambridge [UK]. The problem with pancreatic
cancer is that it’s pretty insensitive to chemotherapy. We started
testing the efficacy of gemcitabine in GEMMs [genetically
engineered mouse models] of pancreatic cancer, and found that it
didn’t work well. Surprisingly, gemcitabine worked much better
when we prepared subcutaneous transplantation mouse cancer
models, which are used bymost researchers and corporations. It also
didn’t matter if the subcutaneous tumors were of mouse or human
origin. We soon came to realize that impaired drug delivery was
behind the chemoresistance of GEMMs, specifically because
the vasculature was poor compared with transplanted tumors.
We confirmed this independently by showing that human
PDA [pancreatic ductal adenocarcinoma] samples showed
hypovascularity. We decided to take it further – since nobody
would publish this observation alone – by looking at whether
disrupting the stromamight positively impact tumor vasculature and
improve drug delivery. The first compound we looked at was an
inhibitor of Smoothened (Smo) in the Hedgehog pathway. It turned
out that Smo inhibition depleted stromal abundance in the
pancreatic tumors in our mouse model, and the number of blood
vessels sprouted way up. When we administered the Smo inhibitor
at the same time as gemcitabine, we could show that the drug got in
the tumour and killed cancer cells, leading to tumor shrinkage in
some of the mice. The animals lived for a couple of weeks longer,
and then they all died. We looked in the tumours and the number of
blood vessels had gone back down again and the stroma was
different.
Based on these data, we hypothesized that we could fix the
perfusion problem to improve drug delivery. The company that
we worked with, Infinity, was very enthusiastic about these results
and did clinical trials for the Smo inhibitor right away. The Phase I
trial showed that it wasn’t dangerous, and it moved into a
randomized Phase 2 trial in which patients underwent
chemotherapy, also using gemcitabine, with and without the
Smo inhibitor. Although this trial still hasn't been formally
published, they realized that the patients who had received both
drugs actually died faster, so the trial was halted. When people
called me to talk about what had happened, the first thing I asked
was ‘what do the samples show?’, and they said, ‘what samples?’ I
became very frustrated not only at the outcome but in the way that
trials are designed, without advice from scientists and without
looking at the findings scientifically. Ken, who by now had set up
his own lab studying the hedgehog signaling pathway in pancreatic
cancer, was obviously troubled by this too, and so he went back to
mice and realized that if you only gave a Smo inhibitor, you would
promote a very aggressive form of pancreatic cancer and the
animals died with rampant cachexia, even though the tumors were
smaller. His colleague at UPenn, Ben Stanger, confirmed this
genetically. When I talked to the clinicians who did the trial, they
told me that the patients got worse on both drugs but not because
the cancer was growing. Patients got worse because their body
collapsed. Out of this disappointment came this fascinating
observation that drove us to go back to look at what the pancreas
tumour is really made out of. We developed a new organoid model
of pancreas cancer with Hans Clevers when we moved back to the
US, and have made some headway using this model to understand
what’s going on at the cellular level.
Despite the failure of the trial, I firmly believe that our pre-clinical
experiments with mice put us on the right track by showing that the
barrier of drug delivery is what we need to work on, and we need to
study it scientifically to make sure that we don’t cause other
physiological problems by interfering. It’s not the same as
unplugging the sink in your kitchen: if you’re going to alter
biology in the non-neoplastic compartment, you need to remember
that this compartment is highly adaptable.
“Identify the problem, understand it at
least to the level where you have therapies
that can help that patient, and then let
them return to their families…That’s
where I want cancer to be, and it’s not
there yet.”
Is this what motivated you to move over to Cold Spring
Harbor?
My plan was to set up a preclinical facility that did very deep
science using the mouse models and organoid models, but
simultaneously establish a carbon copy of that in a human clinic.
As you know, Cold Spring Harbor is a basic science campus with
no hospital nearby and no medical students running around, so we
have established a partnership with a very large healthcare
provider in Long Island called Northwell Health. The idea
behind this relationship was that we could build a Phase 0/Phase
I experimental therapeutic facility, where proof-of-concept,
proof-of-mechanism clinical trials can be performed; where
patients can remain from 24 hours to several days undergoing
multiple biopsies, pharmacological monitoring, imaging and so
forth to answer the question: is the scientific hypothesis correct?
We’ve hired a great clinician scientist to run the facility, Robert
355
A MODEL FOR LIFE Disease Models & Mechanisms (2017) 10, 353-357 doi:10.1242/dmm.029975
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Maki, who was my senior resident when I was an intern at the
Brigham.
My vision for the future of cancer research is that the patient
comes into your hospital, you get a biopsy, you perform molecular
diagnostics, you perform pharmacological testing either on a piece
of the tumor itself or an organoid generated from the tumor, and then
you invite the patient to stay with you until you have a therapy that
you know is helping them. Identify the problem, understand it at
least to the level where you have therapies that can help that patient,
and then let them return to their families. This is how the cardiology
field works: if you have chest pain and they’re pretty sure you have a
blockage in your artery, you’re not going home until they know
where that blockage is and have fixed it! That’swhere I want cancer
to be, and it’s not there yet.
“Organoids are crazy interesting, and
when I see other people in the pancreatic
cancer field I tell them, you should stop
what you’re doing and work on these
because it’s the faster wayof studying this
disease.”
You’ve mentioned organoids, which I know you’re pretty
involved in with Hans Clevers. What are your plans for
organoids of pancreatic cancer?
Organoids are a really terrific model of a patient’s tumour that you
generate from tissue that is either removed at the time of surgery or
when they get a small needle biopsy. Culturing the tissue and
observing an outgrowth of it is usually successful and when you
have the cells, you can perform molecular diagnostics of any type.
With a patient-derived organoid, you can sequence the exome and
the RNA, and you can perform drug testing, which I call
‘pharmacotyping’, where you’re evaluating compounds that by
themselves or in combination show potency against the cells. A
major goal of our lab is to work towards being able to use organoids
to choose therapies that will work for an individual patient –
personalized medicine.
Organoids could be made moot by implantable microdevices
for drug delivery into tumors, developed by Bob Langer. These
devices are the size of a pencil lead and contain reservoirs that
release microdoses of different drugs; the device can be injected
into the tumor to deliver drugs, and can then be carefully
dissected out and analyzed to gain insight into the sensitivity of
cancer cells to different anticancer agents. Bob and I are kind of
engaged in a friendly contest to see whether organoids or
microdosing devices are going to come out on top. I suspect that
both approaches will be important for pharmacotyping cancer
patients in the future.
From the science side, we use organoids to discover things about
pancreatic cancer. They’re great models, probably the best that I
know of to rapidly discover new things about cancer because you
can grow normal tissue as well as malignant tissue. So, from the
same patient you can do a comparison easily to find out what’s
different in the tumor. Organoids are crazy interesting, and when I
see other people in the pancreatic cancer field I tell them, you should
stop what you’re doing and work on these because it’s the faster way
of studying this disease.
Let’smove a little bit away from the science. You’ve bounced
back and forth a bit between theUK and theUS; what are the
differences you’ve seen between the approaches used on
both sides?
Scientists in the UK and the US are similar in most regards but there
are some differences. In the UK, people tend to think before they
jump, they tend to talk to each other about their ideas a lot more that
we do here in America, they meet twice a day to discuss things –
often during tea breaks – and they tend to experiment less. I’d say in
America we do ten experiments to every two that are performed in
the UK. But we tend to do a lot of experiments that don’t work. I
would say that the two experiments they do in the UK don’t
necessarily work either, but probably one does. I feel that this is a
cultural difference: the British tend to spend less money doing
things but spend more time thinking about them. It doesn’t mean
they’re smarter, it’s just their approach to life. I found it refreshing, I
never stopped to have tea at the beginning of the day or the end of
the day but a lot of people whoworked in my lab did. I would eat my
lunch in my office while working but I probably loosened up a little
bit by the end of the six years that I was there and spent more time
talking to people. I really loved my time there, my colleagues were
spectacular and I did some terrific science there. I hope that the
people who read this think about doing some research abroad, out of
their comfort zone.
“I tell my post-docs, roll your sleeves up
and get your hands dirty.”
You’ve trained a lot of peoplewho have gone on to have some
success. What type of mentor are you?What are your tips for
running a successful lab?
First and foremost, I try to identify people who have an internal
passion about solving problems, because you can’t make people
passionate, though you can make them smarter. Once we’ve worked
out what they’re excited about, I help with the development of the
idea and how they’re going to go about it, but it’s very important that
they have ownership. As a mentor, I explain that I don’t have all the
answers but I have an approach that seems to bear fruit and if they’re
passionate about solving a problem, then I will help them in any way
I can. I’ve developed a mnemonic for what I think is the ideal
approach to science – PHENOM, which stands for P is problem, H
is hypothesis, E is experimental methods, N is notebook, O is
oration, M is meeting. I tell them, figure out what problem you want
to solve, develop your own hypotheses and always use multiple
experimental approaches, because if your hypothesis is right, they
will support it and if your hypothesis is partially right, they will at
some point show you why you’re wrong. I also tell them you have to
love to work. My work ethic comes from upbringing; I grew up
catching butterflies and snakes and everything else, rather than
sitting and wondering if one day I’ll catch one. So I tell my post-
docs, roll your sleeves up and get your hands dirty. Make
collaborations with people who can help you when you have no
clue what to do, but don’t stop doing experiments because you need
data that you can interpret and analyze. That’s the N of PHENOM:
notebook. Figure out what you’ve got, write it down and think about
it. It’s common to get stuck when we have no clue what the data’s
telling us and that’s when you should become British, when you
need to talk to people. Scientists love talking about data. We then
come to the O, which refers to oration – this is where I emphasize the
importance of learning to give a talk, and M is for meeting; to meet
colleagues and let them help you. My approach might not work for
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everybody, but I love what I do and I wouldn’t trade it in for
anything, so I guess I primarily lead by example.
“You have to be resilient to be a scientist.
You have to enjoy the ride, enjoy working
hard, and recognize not everything has to
work the first time.”
A lot of people coming out of labs now are concerned about
the future of research. Do you have any advice to them?
When I was their age the fields of molecular biology and cancer
research, and the biotech sector were much smaller so there was less
competition. Now it is harder to win a grant or publish papers. Nine
out ten times you send a paper to a high-impact journal, it doesn’t get
accepted either. You have to be resilient to be a scientist. You have to
enjoy the ride, enjoy working hard and recognize not everything has
to work the first time. If you’re passionate about what you’re doing
and it’s original, you’re going to be fine. But I think that we as
professors need to be more vocal that our path is not for everyone, it’s
for the people who will work hard and not get disappointed when
their paper doesn’t get accepted the first time. Some people think we
train too many PhD students and too many post-docs, but I don’t
agree with this at all: I think we need educated people and critical
thinkers to fill all sectors in our society. Somebody I trained was
supposed to go to medical school, but he became a high-school
chemistry teacher. He realized his passion was to teach because he
was my best darn tech, teaching everybody else how to do things! I
think we need to encourage our trainees to find what they really love
doing.Manyofmy post-docs love science because they feel the joy of
performing experiments, but I have also trained some great post-docs
who write well, think well and speak well, but are just not
experimentalists. So their path should be something else, since they
have different skills and passions. This doesn’t mean they have failed
but rather that they recognize their real strengths.
I also think we need to stop spreading this concept of doom and
gloom in the job market and recognize the tremendous opportunities
we now have in biomedical science that we didn’t in the past.
In cancer, the number of things that we can do to help patients today
is huge compared to even ten years ago. The field of cancer
immunology, for example, came out of nowhere. Look at it now: it’s
humungous!What we do need to do is encourage our people towork
on original areas to give them the best shot of having a job in
academia – if that’s what they want to do – but also be honest with
them that another path could make them happier. The post-docs who
come from foreign countries are in a genuinely tough spot as they
may not have job opportunities back home, and I would love to find
easier ways to provide support to incorporate them in the academic
job market in the US.
That’s a thoughtful point. To finish up, if not science, what
career would you have chosen? You can’t say medicine.
Oh I can’t say medicine? I really like medicine. OK, I wanted to be
a marine biologist when I was little. So Jacques Cousteau was one
of my heroes. But I never learnt to dive; that’s on my bucket list
now.
What do you do for fun at Cold Spring Harbor?
I have a family who keeps me balanced and I’ve taken up fishing as
my hobby here. I’ve concluded that I could never become a
professional fisherman because I don’t catch enough fish, but I
really love being out on the water. Cold Spring Harbor is one of the
most beautiful spots on the planet and so I’m blessed to be here.
What one thing would people be surprised to learn about
you?
I’m a huge [Chicago] Cubs fan - that’s something that not many
people know because I’m too embarrassed to wear my Cubs hat! I
wore it once on a holiday in the Caribbean and people stopped me
and said, ‘I respect you, but I feel real sorry for you’. I thought, I
work on pancreas cancer and here are people feeling sorry for me
based on the sports teams that I like! But we did finally win the
World Series this year, after 108 years. It will take us less time to
beat pancreatic cancer!
DMM greatly appreciates David’s willingness to share his unique thoughts and
experiences with Ross Cagan, DMM Senior Editor. The final piece has been edited
and condensed by Paraminder Dhillon, with David’s approval.
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